Zhongchao (NASDAQ:ZCMD – Get Free Report) and Progyny (NASDAQ:PGNY – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.
Institutional and Insider Ownership
1.7% of Zhongchao shares are owned by institutional investors. Comparatively, 94.9% of Progyny shares are owned by institutional investors. 28.6% of Zhongchao shares are owned by insiders. Comparatively, 9.9% of Progyny shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings and price targets for Zhongchao and Progyny, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zhongchao | 1 | 0 | 0 | 0 | 1.00 |
| Progyny | 0 | 3 | 8 | 1 | 2.83 |
Profitability
This table compares Zhongchao and Progyny’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zhongchao | N/A | N/A | N/A |
| Progyny | 6.00% | 15.98% | 10.65% |
Risk and Volatility
Zhongchao has a beta of -0.01, suggesting that its stock price is 101% less volatile than the S&P 500. Comparatively, Progyny has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.
Valuation & Earnings
This table compares Zhongchao and Progyny”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zhongchao | $11.38 million | 0.11 | -$6.31 million | N/A | N/A |
| Progyny | $1.29 billion | 1.56 | $58.52 million | $0.92 | 28.55 |
Progyny has higher revenue and earnings than Zhongchao.
Summary
Progyny beats Zhongchao on 12 of the 13 factors compared between the two stocks.
About Zhongchao
Zhongchao Inc. provides healthcare information, education, and training services in the People's Republic of China. The company offers online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes of popular medical topics, interactive case studies, academic conference and workshops, continuing education courses, and articles and short videos with educational healthcare content. It also provides customized medical courses and medical training services; and patient management services through online platform under the Zhongxun brand. The company operates through its mdmooc.org online platform under the MDMOOC brand; and Sunshine Health Forums, a Wechat subscription account and mobile app. It serves enterprises, non-for-profit organizations, and medical journals, as well as healthcare professionals, nurses, doctors, and other healthcare workers. The company was founded in 2012 and is headquartered in Shanghai, China.
About Progyny
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Receive News & Ratings for Zhongchao Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zhongchao and related companies with MarketBeat.com's FREE daily email newsletter.
